Dr. Afshin Javili, an Iranian doctor, is a Cosmetic Surgeon and ENT Specialist. He is a medical doctor from Tehran University of Medical Science (1997), ENT Specialist from O.O.Bogomolets National Medical University (NMU) Kiev Ukraine (2009). Since 2012 he has been working on Non Surgical Aesthetic Procedures, he has gone through these procedures for hundreds of his patients in Iran. In 2014 he started working on Lifting and Filling Threads and now Dr. Javili is one of the most experienced and best doctors in the field and non-surgical methods of aesthetic medicine overly in the world. He has already managed and held a dozen teaching courses and workshops as a teacher so he is one of the most experienced and well-known teachers in the field in the world. He speaks Persian, English, Russian, German, Ukrainian and Turkish. He was born in 1970 in Iran and recently moved to Turkey and lives in Istanbul.
What are these?: They are absorbable medical threads that will be inserted under the skin for Aesthetic problems or remodeling. What’s the importance of them?: They are an excellent alternative therapy of big and complicated surgeries in Aesthetic medicine and the procedure is Non-Surgical and very easier. In which kind of branches of medicine they might be used?: Dermatology, E.N.T, Plastic Surgery, Neurology, Neurosurgery, Maxillofacial Surgery, Ophthalmology. What are their indications?: Wrinkles , dynamic and static lines of skin, Treatment of asymmetries, Lifting of skin, Skin tightening and contour laxity, Rejuvenation and delay cutaneous aging, Volume loss under the skin, Alternative of botox and fillers, Scars, Sharpening of columns , lines and borders of skin, Skin brightness. What are they made of?: There are 3 types of threads now. P.D.O (polydioxanone) P.L.L.A (Poly-L-Lactic Acid) P.C.L (Polycaprolactone) How does it works?: At first it has an instant skin lifting and filling effects through mechanical effects, after that resolving process will begin and among this, cellular renewal , collagen stimulation and neovascularisation will be occurred and it will be caused to improve skin texture, fine lines ,stretching, elasticity and skin tightening. How long does it take for threads to dissolve? P.D.O 3-6 MONTHS P.L.L.A 12-18 MONTHS P.C.L 24-36 MONTHS How soon will we see results and how long they remains?: The best result will be seen after 3 months of insertion and depends on the type of the thread. It will be continued more than 2 years or up to many years. What are their benefits?: minimally invasive procedure, short time (15 – 30 minutes), surprisingly safe treatment (very few side effects), very natural, tissue making, cost effective in compare of surgery, ambulatory procedure, long lasting effects. After the procedure: Some mild swelling and soreness for 1 to 2 days and a mild sensation of tightness up to 2 weeks and with a good ice packing there is no bruising. Side effects: If happened are easily manageable and serious side effects are mostly related to the technique of insertion so if the doctor is skilled , well trained and experienced there are no side effects at all.
Isao Kitajima is the executive vice president, University of Toyama in Japan. He graduated from Kagoshima University School of Medicine in Japan (1982). He conducted research at The Scripps Research Institute (1990) in the USA. His research interest is in the molecular pathology of immunological disorders.
Persistent pruritus is a typical characteristic of atopic dermatitis (AD), although its etiology has not been fully elucidated. IKK2, a component of the IkB kinase complex, exerts pro-inflammatory responses, whereas its deficiency in keratinocytes paradoxically causes skin inflammation. In this study, we generated in which IKK2 is lacked in dermal fibroblasts. Nestincre;Ikk2f/f mice spontaneously developed skin inflammation limited to the face and their phenotypes are similar to those of AD patients. Moreover, these mice exhibited extensive itch behaviors such as scratching and biting as they grew up. Thus, we named Facial Atopic Dermatitis with Scratching (FADS) mice. Itch behaviors were significantly attenuated by the topical treatment with tofacitinib (Jak1/3 inhibitor) but not tacrolimus. FADS mouse is a novel animal model exhibiting severe itching. FADS will be useful in clarifying the etiology of itching accompanied with AD.
Dr. Kiticharoensak Ornrapee has completed her medical degree from Chulalongkorn University, Thailand and master’s degree of clinical dermatology from Cardiff University, UK. In addition, she earns a MBA degree from Peking University, China and did the exchange program at Waseda University, Japan. Dr. Ornrapee was a medical advisor at Novartis (Thailand). After graduating from UK, she is an aesthetitian at Hertitude clinic in Bangkok, Thailand.
Retinoids refer to all natural and synthetic products having a structure or biological activities similar to vitamin A, which helps to modulate the function of homeostasis, metabolism, epithelial growth and immune regulation as well as inflammation via retinoid receptors. Recently, there has been a growing interest in retinoids in the management of UV-related skin conditions, including skin cancer, solar ageing as well as dyspigmentation, which cause a huge dermatological and psychological burden on patients. However, scientific evidence and a standard guideline of retinoids on these conditions are still limited. Skin cancer is caused by accumulative DNA damage by UVR along with an impaired DNA repair mechanisms. Retinoids seem to have a chemopreventive effect by modulating the repair processes and programmed cell death. Acitretin appears to be effective in the chemoprevention of SCC among OTRs but due to the side effects of systemic retinoids, the application should be limited to high-risk populations and the rebound effect may occur after discontinuing medication. UVR also causes skin ageing that leads to a structural and functional deterioration of skin. Wrinkling, mottled hyperpigmentation and solar lentigo can be improved by long-term use of topical retinoids, such as topical tretinoin an adapalene. The efficacy seems to be correlated with the strength of retinoids along with their side effects, which can gradually subside overtime. Thus, low concentration of retinoids along with an emollient as well as a sunscreen application should be introduced during the initiating period to avoid drug interruption or discontinuation. Due to several limitations of clinical studies, the efficacy of cosmeceutical products on skin ageing is still controversial. Besides, long-term use of topical tretinoin may improve melasma but a treatment combination along with topical retinoids is suggested to yield a satisfactory result with minimal side effects. (OTR- Organ transplant recipient, SCC- Squamous cell carcinoma, UVR-Ultraviolet radiation)
Dr. Palki Sharma has completed her MBBS at the age of 24 years from Jammu University, India. Due to her compassion in serving the underprivileged she worked as a medical officer with Government of India for 4 years in rural parts of India. She completed her Masters in Clinical Dermatology in 2019 with a distinction from Cardiff University, School of Medicine UK.
Hidradenitis suppurative is a chronic inflammatory skin condition. It is characterized by recurrent, painful inflammatory nodules, and abscess in the intertriginous parts of the body, leading to extensive scarring and disfigurement. The exact pathogenesis of HS is unknown. However, various studies have supported the follicular occlusion theory. The primary defect in HS is believed to cause occlusion and subsequent inflammation of the pilosebaceous unit under the influence of genetic, hormonal, immune, smoking, obesity, and mechanical frictional factors. Although, it is not a life-threating skin condition, its relapsing and disfiguring nature leads to a significant impact on the patient’s quality of life. A sizeable body of research demonstrates obesity as one of the most common comorbidities associated with HS. Moreover, obesity is considered to be one of the risk factors for the development of metabolic syndrome and cardiovascular abnormalities, which are commonly associated with HS. At present, there is a lack of data on there being a direct association between HS and obesity and there is no data available showing a cause and effect relationship between weight or BMI and the disease severity. Treatment wise there is a lack of an absolute effective management modality with no definitive cure. Therapeutic studies in HS have shown a decreased efficacy of patients towards various treatment modalities, including biologics. Studies evaluating the efficacy of biologics in autoinflammatory diseases have suggested obesity to have a negative impact on anti-TNF therapy. Unfortunately, at present, there are no studies conducted on HS that can verify this theory, chiefly due to imprecise knowledge linking obesity and HS. Thus, for this paper, the scientific studies surrounding the multifaceted association between HS and obesity have been reviewed, suggesting that obesity might be a severity factor of HS. Therefore, opting a different course of treatment may help in the management of overweight and obese HS.
Sham AlZahabi has graduated from the American University in Cairo with MSc in Chemistry, was senior RnD researcher at local cosmetic factory, Eva cosmetics for 3 years. Following her masters, got awarded several scholarships in both Cambridge University and Oxford University to continue her research. She went to Cambridge to begin her PhD journey, where she studied biomimicry of skin modeling in the group of Professor Duer, and interrupted her study to come back to Egypt and open her skin clinic, Dao Derma, where now she’s continuing both.
This work aims to investigate the potential advantage of using Prickly Pear (PP) seed oil to develop nanostructured lipid carrier (NLC) for topical delivery of vitamin A. The release patterns of four PP-based NLC formulations with varying amounts of surfactant to solid lipid ratio, and amounts of Prickly Pear Seed oil have been developed using the hot homogenization method, and compared with a solid lipid nanoparticle (SLN) formulation that is free of PP oil. The effect of the variation in the constituting matrix of the nano-carriers on entrapment efficiency, in-vitro release behavior, and ex-vivo permeation using Franz Diffusion Cell, was investigated. Additionally, particle size and polydispersity index (PDI) upon storage, zeta potential, and thermal behavior were characterized. PP-based NLCs exhibited smaller particle size in the range of 215-244 nm, and PDI < 0.3. In contrast, SLN having no PP oil had a larger diameter of 365nm, with heterogeneous distribution (0.92 PDI). In assessing the in-vitro release, an inverse relationship was observed between the diffusion flux and the entrapment efficiency. The changes in the constituting matrix of the NLCs lead to a significant potential variation in their properties, and hence allowing it to be tailored for specific usages.
Chief Dermato-laser & Hair Transplant Surgeon In Aura Skin Institute, Chandigarh, India. Program Director For IADVL Fellowship in ‘Lasers & Aesthetic Dermatology’. Recipient of Young Dermatologist Forum Award,2008 for work on Cutaneous Vasculitis in Dermacon 2008. Reviewer for prestigious journals like IJDVL ,Stem cell investigation journal,, JCAS, JCD, JCMS and IDOJ. Filed a Patent protocol on non-surgical facelift. Innovated LA-PEEST , a novel fast acting Vitiligo surgery. Proposed a Global drooping and wrinkle classification for aging face. Invited faculty in ‘International Conference on Regenerative Surgery, Rome, 2017and also for WCOCD, Croatia,2018 to present innovative research work on FUE & PRP Therapy.
Background: Treating melasma is a challenge due to suboptimal efficacy and recurrence encountered with most modalities. There is inadequate literature regarding the use of lasers for melasma in Indian skin. We compared three modalities SSR (Super Skin Rejuvenation 540 nm), PQSNDY (pixel Q-switched Nd: YAG 1064 nm), and ablative pixel-Er: YAG (2940 nm) laser in melasma, amongst Indian patients. Sixty patients of recalcitrant melasma were enrolled and randomized into three groups with 20 patients each. These were treated with SSR, low fluence PQSNDY, and pixel-Er: YAG, respectively, for five sessions at 3-week intervals. Results were evaluated using modified melasma area severity index (mMASI) by blinded comparison of digital photographs at baseline, each visit and 6 months (i.e. 2 months after the last session).All groups showed a highly significant reduction in the mMASI score (p < .001). Pixel-Er: YAG maximally reduced mMASI and homogeneity (p < .001), while the other groups showed a more uniform fading. Epidermal melasma had best results with SSR and PQSNDY (p < .001), while recalcitrant cases of dermal and mixed melasma with pixel-Er: YAG laser (p < .001). There was no persistent or rebound pigmentation observed. All three modalities are effective and safe for melasma in Indian patients. Fractional technology, low fluences, adequate recovery time between sessions and a sound maintenance plan ensure efficacy and safety.